The global retinoblastoma treatment market is anticipated to grow at a significant CAGR during the forecast period. Retinoblastoma treatment options include chemotherapy, radiation therapy, laser therapy, and many more. In some cases, surgery was also recommended by the physician as the option for retinoblastoma treatment. Retinoblastoma is a rare childhood cancer of the eye that starts from the retina that is sensitive to light. It is located in the nerve tissue in the back of the eye. In recent times, a huge advance has been observed in the diagnosis as well as treatment of the retinoblastoma which has increased the rate of cure to 95%in children with retinoblastoma. The tumors can be present in one or both eyes of the child, and in some rare cases, it spreads to other parts of the body as well which makes the retinoblastoma treatment difficult. Retinoblastoma cancer condition has the possibility of inheriting the condition within a family, besides in some children, it can occur without any family history of the disease.

Additionally, the high cost associated with retinoblastoma treatment presents challenge for the growth of the retinoblastoma treatment market. Additionally, the low awareness and late diagnosis of disease in children living in developing countries will also hamper the growth of the retinoblastoma treatment market during the forecast period. Moreover, the side effects of chemotherapy during the retinoblastoma treatment such as bone marrow suppression, alopecia, autotoxicity, and nephrotoxicity will lower the adoption of chemotherapy. Hence, the low adoption rate of chemotherapy as the treatment of retinoblastoma will restrict the growth of the market during the forecast period.

Segmental Outlook 

The global retinoblastoma treatment market is segmented on the basis of the treatment type and type of retinoblastoma. Based on the treatment type, the market is sub-segmented into surgery, radiation therapy, laser therapy (photocoagulation), cryotherapy, thermotherapy, and chemotherapy. Further, based on the type of retinoblastoma, the market is sub-segment into non-hereditary retinoblastoma and hereditary retinoblastoma.

Global Retinoblastoma Treatment Market Share by Treatment Type, 2020 (%)

Chemotherapy to Hold a Significant Share

The chemotherapy segment is anticipated to hold a significant share in the retinoblastoma treatment market owing to increasing new chemotherapy and chemo drug availability in the market. For instance, intra-arterial chemotherapy and intravitreal chemotherapy are few of the chemotherapy option available to replace the conventional chemotherapy. Additionally, the adoption of new chemotherapy owing to its effective result in the regression of tumors even in advanced retinoblastoma will also drive the anti-hypertensive market significantly during the forecast period.

Regional Outlooks

The global retinoblastoma treatment market is further segmented based on geography into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold the largest market share in the retinoblastoma treatment during the forecast period owing to the well-developed healthcare structure for cancer treatment in the region. Additionally, the easy availability of retinoblastoma treatment due to the presence of various hospitals with special programs for the retinoblastoma treatment across the region will also drive the retinoblastoma treatment market across the region. For instance, Boston Children’s Hospital offers Dana-Farber/Boston Children’s Retinoblastoma Program that includes a range of multidisciplinary treatment options for retinoblastoma. 

Asia-Pacific to Augment with Considerable Growth Rate in the Market

Asia-Pacific is anticipated to exhibit considerable growth rate in the retinoblastoma treatment market owing to the increasing awareness across the region. Moreover, the government and non-government initiatives across the region will also fuel the retinoblastoma treatment market. For instance, Iksha Foundation is one such non-government body in India that provides financial help for the treatment of retinoblastoma to children with poor financial conditions. Additionally, the developing healthcare sector in countries such as India and China will also boost the growth of the retinoblastoma treatment market across the region during the forecast period.

Market Players Outlook

Some of the players of the retinoblastoma treatment market include Baxter International Inc., Merck & Co. Inc., Sanofi S.A., Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to stay competitive in the market. Further, non-profit organizations are considerably contributing to the market growth. For instance, in March 2019, Children's Hospital Los Angeles received a grant of $1.6 million from the National Institutes of Health (NIH) to study the retinoblastoma. It is a non-profit, pediatric academic medical center located in Los Angeles, US. The study will open new avenues for treatment the treatment of retinoblastoma including various other cancer types.

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global retinoblastoma treatment market. Based on the availability of data, information related to products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.